Reference Preparation for Assay of Some Pregnancy and Cancer Associated Proteins

Bohn, H.; Grudzinskas, J. G.; Rosen, Seymour; Seppålå, M; Tatarinov, Yu. S.; Chard, T.; Klopper, Arnold; Schultz-Larsen, Peter; Sizaret, P; Teisner, B.

doi:10.1016/s0140-6736(80)90403-1

Cited by 15 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we used pregnancy serum pool-derived calibrators for the assays for PAPP-A in ACS. The reference material we used is WHO IRP 78/610, which is also derived from a pregnancy serum pool (27 ). As PAPP-A is present mainly as a complexed form in pregnancy serum, the calibrators, as well as the WHO reference material, are obviously not homologous to PAPP-A in ACS.…”

Section: Discussionmentioning

confidence: 99%

Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes

et al. 2006

View full text Add to dashboard Cite

Background: Pregnancy-associated plasma protein-A (PAPP-A) concentrations are increased in the circulation of patients with acute coronary syndromes (ACS) and are associated with future adverse cardiac events. PAPP-A in ACS differs from PAPP-A in pregnancy in that PAPP-A in ACS is not complexed with the proform of eosinophil major basic protein (proMBP). We investigated the effect of antibody selection on the utility of PAPP-A assays for measurement of PAPP-A in pregnancy and/or ACS, and whether immunoassays for PAPP-A in pregnancy are suitable for PAPP-A in ACS. Methods: We constructed 2-site sandwich time-resolved immunofluorometric assays using 22 monoclonal antibodies raised against pregnancy serum PAPP-A. All antibodies were studied in pairs, with each antibody used as either capture or tracer. We compared the reactivity of each antibody combination with PAPP-A/ proMBP complex derived from pregnancy sera or with uncomplexed PAPP-A extracted from atherosclerotic plaques. Recombinant human PAPP-A and proMBP were also used to determine the specificity of the antibodies. We confirmed all major findings with serum samples collected from patients with myocardial infarction. Results: Six monoclonal antibodies reacted with the proMBP subunit of the PAPP-A/proMBP complex.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes

et al. 2006

View full text Add to dashboard Cite

show abstract

“…As a standard WHO IRP 78/610 (WHO International Laboratory, Statens Seruminstitut, Denmark) was used. When the contents of one ampoule were dissolved in 0·75 ml of distilled water, the concentration of SP1 was 100 IU/l (Bohn et al, 1980).…”

Section: Methodsmentioning

confidence: 99%

Schwangerschaftsprotein 1 (Sp1) as a Maternal Serum Marker for Down Syndrome in the First and Second Trimesters

et al. 1997

View full text Add to dashboard Cite

“…21 The absence of an international reference standard is a continuing issue in striving to improve uniformity of PAPP-A results between laboratories and methods. The Access w instrument calibrates PAPP-A levels in ng/mL 22 versus other methods that use mIU/mL as the reporting unit. Although disconcerting, this underscores the need for each prenatal screening laboratory to carefully monitor its median MoM levels over time regardless of the methodology chosen, and revise medians when necessary.…”

Section: Discussionmentioning

confidence: 99%

Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access® platform: suitability for use in first trimester Down's syndrome screening

2010

View full text Add to dashboard Cite

Objective To explore the clinical validity of the new Access® pregnancy-associated plasma protein-A (PAPP-A) assay for Down's syndrome screening. Setting Academic hospital. Method Residual serum samples ( n = 416) received for routine first trimester Down's syndrome screening (10-13 weeks) were retrieved from freezer storage and tested using two PAPP-A immunoassay methods. The new Access® assay was specifically compared, on a subset of these samples ( n = 194), with an assay proven to give acceptable Down's syndrome screening performance, the PerkinElmer (PE) AutoDELFIA method. Access® PAPP-A levels were examined in relation to gestational age and maternal weight, and were compared with the PE method by regression and Bland-Altman analyses. Results Access® PAPP-A assay results were highly correlated with the PE AutoDELFIA method ( r = 0.97). PAPP-A levels obtained using the Access® assay increased with advancing gestational age and were inversely related to maternal weight, as expected. The distribution of multiples of the median (MoM) values fit a log Gaussian distribution and the standard deviation of the log MoM (0.2331) matched published estimates. PAPP-A MoM levels in Down's syndrome pregnancies ( n = 6, median 0.30) showed the expected reduction. Conclusion Using an appropriate gestational age-specific median equation, the Access® PAPP-A assay is expected to perform acceptably in first trimester Down's syndrome screening.

show abstract

Reference Preparation for Assay of Some Pregnancy and Cancer Associated Proteins

Cited by 15 publications

References 0 publications

Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes

Immunoassays Developed for Pregnancy-Associated Plasma Protein-A (PAPP-A) in Pregnancy May Not Recognize PAPP-A in Acute Coronary Syndromes

Schwangerschaftsprotein 1 (Sp1) as a Maternal Serum Marker for Down Syndrome in the First and Second Trimesters

Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access® platform: suitability for use in first trimester Down's syndrome screening

Contact Info

Product

Resources

About